SI2074123T1 - Nove anksiolitične spojine - Google Patents

Nove anksiolitične spojine

Info

Publication number
SI2074123T1
SI2074123T1 SI200731109T SI200731109T SI2074123T1 SI 2074123 T1 SI2074123 T1 SI 2074123T1 SI 200731109 T SI200731109 T SI 200731109T SI 200731109 T SI200731109 T SI 200731109T SI 2074123 T1 SI2074123 T1 SI 2074123T1
Authority
SI
Slovenia
Prior art keywords
anxiolytic compounds
novel anxiolytic
novel
compounds
anxiolytic
Prior art date
Application number
SI200731109T
Other languages
English (en)
Inventor
Jonathan Bayldon Baell
Brad Sleebs
Bernard Luke Flynn
Ian Phillip Street
Nurul Quazi
Chinh Thien Bui
Original Assignee
Bionomics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionomics Limited filed Critical Bionomics Limited
Publication of SI2074123T1 publication Critical patent/SI2074123T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200731109T 2006-10-16 2007-10-16 Nove anksiolitične spojine SI2074123T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198306P 2006-10-16 2006-10-16
PCT/AU2007/001566 WO2008046135A1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds
EP07815371A EP2074123B1 (en) 2006-10-16 2007-10-16 Novel anxiolytic compounds

Publications (1)

Publication Number Publication Date
SI2074123T1 true SI2074123T1 (sl) 2013-03-29

Family

ID=39313499

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731109T SI2074123T1 (sl) 2006-10-16 2007-10-16 Nove anksiolitične spojine

Country Status (13)

Country Link
US (7) US8293737B2 (sl)
EP (2) EP2074123B1 (sl)
JP (4) JP5373613B2 (sl)
AU (1) AU2007312936B2 (sl)
CA (2) CA2954376C (sl)
DK (1) DK2074123T3 (sl)
ES (1) ES2399071T3 (sl)
HK (1) HK1132268A1 (sl)
NZ (1) NZ576036A (sl)
PL (1) PL2074123T3 (sl)
PT (1) PT2074123E (sl)
SI (1) SI2074123T1 (sl)
WO (1) WO2008046135A1 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10954231B2 (en) * 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
AU2007312936B2 (en) 2006-10-16 2013-09-26 Bionomics Limited Novel anxiolytic compounds
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
AU2012222874B2 (en) * 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
AU2012253237B2 (en) * 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines
WO2014036595A1 (en) * 2012-09-04 2014-03-13 Bionomics Limited Compounds and methods for treating diseases or conditions associated with the central nervous system and/or neurite outgrowth
WO2014138812A1 (en) * 2013-03-15 2014-09-18 Bionomics Limited Salts, co-crystals, and polymorphs of an anxiolytic compound
AU2013204159B2 (en) 2013-03-15 2015-05-07 Bionomics Limited A Crystalline Form of an Anxiolytic Compound
WO2019109150A1 (en) * 2017-12-07 2019-06-13 Bionomics Limited Methods of treating agitation
ES2975022T3 (es) 2018-10-18 2024-07-02 Bionomics Ltd Derivados de 6-indan-2-iloxi-3-(morfolina-4-carbonil)-1,8-naftiridin-4-ona y compuestos similares como moduladores del receptor nicotínico alfa 7 de la acetilcolina para el tratamiento de la ansiedad
US20230147869A1 (en) * 2019-09-23 2023-05-11 Bionomics Limited Therapeutic formulations and uses thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) * 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
US3429887A (en) * 1965-01-26 1969-02-25 Sterling Drug Inc 1,7-naphthyridine-3-carboxylic acid derivatives and their preparation
US3506668A (en) * 1965-01-26 1970-04-14 Sterling Drug Inc Method of preparing 8-hydroxy-quinolines
JPS5023037B1 (sl) 1970-12-29 1975-08-05
JPS5023036B1 (sl) 1970-12-29 1975-08-05
JPS5023037A (sl) 1973-07-03 1975-03-12
JPS5023036A (sl) * 1973-07-06 1975-03-12
JPS5132594A (en) * 1974-09-11 1976-03-19 Kanebo Ltd 1 88 nafuchirijinjudotai no seiho
JPS5331690A (en) * 1976-09-01 1978-03-25 Shionogi & Co Ltd Oxadithiacephalosporins
JPS54163596A (en) * 1978-06-09 1979-12-26 Daiichi Seiyaku Co Flonaphlizine derivative
JPS55111486A (en) * 1979-02-19 1980-08-28 Dai Ichi Seiyaku Co Ltd Preparation of pro 3,2,-b -1,8-naphthyridine derivative
JPS55151584A (en) * 1979-05-11 1980-11-26 Dai Ichi Seiyaku Co Ltd Preparation of 1,8-naphthyridine derivative
JPS56115787A (en) * 1980-02-19 1981-09-11 Dai Ichi Seiyaku Co Ltd Preparation of furo (3,2-b)(1,8)naphthyridine derivative
JPS56118081A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Preparation of 6-methoxy-1,8-naphthyridine
JPS56118083A (en) * 1980-02-22 1981-09-16 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)(1,8)naphthyridine derivative
JPS5726688A (en) * 1980-07-24 1982-02-12 Dai Ichi Seiyaku Co Ltd Furo 3,2-b 1,8-naphthyridine-7-carboxylic acid derivative
JPS57109790A (en) * 1980-12-26 1982-07-08 Dai Ichi Seiyaku Co Ltd Furo(3,2-b)1,8-naphthyridine-7-carboxylic acid derivative
US4404201A (en) * 1981-11-13 1983-09-13 Warner-Lambert Company Cephalosporins
JPS5993080A (ja) * 1982-11-18 1984-05-29 Sumitomo Chem Co Ltd １，５−ナフチリジンカルボン酸誘導体
EP0341990B1 (en) 1988-05-10 1994-11-09 Imperial Chemical Industries Plc Cephalosporins, process for their preparation and pharmaceutical compositions
US5095015A (en) * 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
US5182386A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5182290A (en) * 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
IT1251202B (it) * 1991-09-13 1995-05-04 Mediolanum Farmaceutici Spa 6-amminochinoloni, sintesi ed impiego come antibatterici
US5212310A (en) * 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5306819A (en) * 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
US5750702A (en) * 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
US5804686A (en) * 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) * 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6013650A (en) * 1996-03-14 2000-01-11 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
AU2218997A (en) * 1996-03-22 1997-10-10 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US5723462A (en) * 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
CA2301599C (en) * 1997-08-25 2003-03-25 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
US6143760A (en) * 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
WO1999043682A1 (en) * 1998-02-26 1999-09-02 Neurogen Corporation 2-(het-)aryl-4-(cyclic amino substituted) heteroaryl fused pyridine derivatives, their preparation and their use as (ant-)agonists for gaba (a) brain receptors
DE19826050A1 (de) 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
US6177569B1 (en) * 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CA2371472A1 (en) * 1999-05-06 2000-11-16 Neurogen Corporation Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
AU1481701A (en) * 1999-11-12 2001-06-06 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
US6723332B2 (en) * 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
US6828329B2 (en) * 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US6423956B1 (en) * 2000-07-28 2002-07-23 Optical Biopsy Technologies Fiber-coupled, high-speed, integrated, angled-dual-axis confocal scanning microscopes employing vertical cross-section scanning
EP1337523B1 (en) * 2000-08-16 2005-10-19 Neurogen Corporation 2,4-substituted pyridine derivatives
WO2002020492A1 (en) * 2000-09-06 2002-03-14 Neurogen Corporation Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
MXPA03007834A (es) * 2001-03-01 2003-12-08 Pfizer Prod Inc Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
ATE345344T1 (de) * 2001-03-27 2006-12-15 Neurogen Corp (oxopyrazolo 1,5aöpyrimidin-2-yl) alkylcarbonsäureamide
WO2003045920A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
ES2319176T3 (es) * 2002-05-14 2009-05-05 The Regents Of The University Of California Acidos quinolona-carboxilicos sustituidos, sus derivados, sitio de accion y uso de los mismos.
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
AR042486A1 (es) * 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
JP2005162726A (ja) * 2003-01-24 2005-06-23 Tanabe Seiyaku Co Ltd ピラゾロピリミジン化合物およびその製法
US20050031652A1 (en) 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
JP2006514964A (ja) * 2003-03-12 2006-05-18 アボット・ラボラトリーズ 抗菌剤としてのナフチリジン誘導体
US7470706B2 (en) * 2004-01-31 2008-12-30 Sanofi-Aventis Deutschland Gmbh Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7402674B2 (en) * 2004-01-31 2008-07-22 Sanofi-Aventis Deutschland Gmbh, 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004971B3 (de) 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel
US7498341B2 (en) * 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
DE102004004972B3 (de) * 2004-01-31 2005-09-15 Aventis Pharma Deutschland Gmbh Heterocyclisch substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE502005007840D1 (de) * 2004-01-31 2009-09-17 Sanofi Aventis Deutschland 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
EP1809605B1 (en) 2004-11-01 2010-08-11 F. Hoffmann-La Roche AG Quinolines as allosteric enhancers of the gaba-b receptors
CA2589629A1 (en) 2004-12-03 2006-06-29 Merck & Co., Inc. Quinoline tachykinin receptor antagonists
MX2007014929A (es) 2005-06-02 2008-02-15 Hoffmann La Roche 3-metansulfonilquinolinas como mejoradores de gaba-b.
PL1931660T3 (pl) 2005-09-29 2012-12-31 Sanofi Sa Pochodne fenylo-[1,2,4]-oksadiazol-5-onu z grupą fenylową, sposoby ich wytwarzania i ich zastosowanie jako środków farmaceutycznych
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
AU2007312936B2 (en) 2006-10-16 2013-09-26 Bionomics Limited Novel anxiolytic compounds
AR076687A1 (es) 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
SG191875A1 (en) 2011-02-07 2013-08-30 Biogen Idec Inc S1p modulating agents
AU2012222874B2 (en) 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
EP2680842A4 (en) 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
AU2012253237B2 (en) 2011-05-12 2015-09-24 Bionomics Limited Methods for preparing naphthyridines

Also Published As

Publication number Publication date
CA2954376A1 (en) 2008-04-24
CA2666219A1 (en) 2008-04-24
JP2013189453A (ja) 2013-09-26
ES2399071T3 (es) 2013-03-25
US20180105524A1 (en) 2018-04-19
US20100105678A1 (en) 2010-04-29
US8906912B2 (en) 2014-12-09
HK1132268A1 (en) 2010-02-19
JP6138191B2 (ja) 2017-05-31
DK2074123T3 (da) 2013-01-14
EP2074123A4 (en) 2011-09-07
EP2540722A1 (en) 2013-01-02
PL2074123T3 (pl) 2013-04-30
US20150166534A1 (en) 2015-06-18
US8614212B2 (en) 2013-12-24
JP2017105818A (ja) 2017-06-15
EP2540722B1 (en) 2016-06-08
AU2007312936B2 (en) 2013-09-26
WO2008046135A1 (en) 2008-04-24
US9975892B2 (en) 2018-05-22
JP5373613B2 (ja) 2013-12-18
JP6506322B2 (ja) 2019-04-24
NZ576036A (en) 2010-10-29
JP5739476B2 (ja) 2015-06-24
US20170183347A1 (en) 2017-06-29
EP2074123A1 (en) 2009-07-01
US9573945B2 (en) 2017-02-21
EP2074123B1 (en) 2012-12-05
US10233181B2 (en) 2019-03-19
US20130012509A1 (en) 2013-01-10
US20140045839A1 (en) 2014-02-13
CA2666219C (en) 2017-02-07
US8551990B2 (en) 2013-10-08
US20130012508A1 (en) 2013-01-10
US8293737B2 (en) 2012-10-23
PT2074123E (pt) 2013-01-22
JP2010506829A (ja) 2010-03-04
JP2015155444A (ja) 2015-08-27
CA2954376C (en) 2019-06-11
AU2007312936A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
HK1132268A1 (en) Novel anxiolytic compounds
EP2034838A4 (en) NOVEL CONNECTIONS
EP2032142A4 (en) NOVEL CONNECTIONS
EP1981596A4 (en) NEW CONNECTIONS
GB0603550D0 (en) Novel compounds
EP1981900A4 (en) NEW COMPOUNDS
GB0605462D0 (en) Novel compounds
GB0602900D0 (en) Novel Compounds
EP2031965A4 (en) NEW COMPOUNDS
GB0607840D0 (en) Novel compounds
GB0600483D0 (en) Novel compounds
GB0608452D0 (en) Novel compounds
GB0607892D0 (en) Novel compounds
GB0624901D0 (en) Novel compounds E
GB0603779D0 (en) Novel compounds
GB0606527D0 (en) Novel compounds
GB0602133D0 (en) Novel compounds
GB0602237D0 (en) Novel compounds
GB0602238D0 (en) Novel compounds
GB0602800D0 (en) Novel Compounds
GB0601728D0 (en) Novel Compounds
GB0603897D0 (en) Novel compounds
GB0603899D0 (en) Novel compounds
GB0603900D0 (en) Novel compounds
GB0604897D0 (en) Novel compounds